NCT Number: NCT03852238
Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)
The main objective of this study is to identify direct carcinogenic factors in the absence of cirrhosis, and the carcinogenesis pathways involved on nonfibrotic liver (NfCHC).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–65 year
Sex eligibility
All sexes
Study type
Observational
Primary location
CHU Amiens, Amiens, France
About this study
Most hepatocellular carcinoma (HCC) complicates cirrhosis, which is often caused by infection with hepatitis B or C viruses, alcohol, obesity, exposure to aflatoxin B1 (AFB1) or hemochromatosis. Nevertheless, 10 to 40% of HCCs can develop on non-cirrhotic terrain and about 5% on nonfibrotic liver (NfHCC). In 20 to 40% of these NfHCCs, no classical HCC risk factor is identified. Some cases could be the result of a transformation of an adenoma. Others may be associated with yet non-formally identified toxins and / or a specific genetic predisposition. While there is a lot of data on alterations of signaling pathways (ß-catenin, AKT / mTOR, Ras / pERK, etc.) in "classical" HCCs, altered pathways remain unknown in most NfHCCs, even in some cases, activation of β-catenin, inactivating mutations of HNF1 or activators of gp130 have been shown. A specific study of NfHCCs, rather rare cancers, represents an opportunity to look for directly carcinogenic factors in the absence of cirrhosis, and to dissect the involved carcinogenesis pathways.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- CASES: patients aged 18 years and older with a diagnosis of NfHCC with anatomopathological examination and showing a HCC according to standard histopathological criteria and an absence of significant fibrosis in non-tumoral tissues with the METAVIR system score or equivalent (F0 or F1) or the Kleiner et al stage of ASH and NASH (≤stade 2); signed informed consent; affiliated or beneficiary of a social security system
- CONTROLS: patients aged 18 years and older without NfHCC at baseline; patients for whom an endoscopy is programmed as part of an assessment of intestinal functional disorders, dyspeptic disorders or screening colonoscopy or hospitalized patients in orthopedic surgery / traumatology or rheumatology departments; signed informed consent; affiliated or beneficiary of a social security system
Exclusion criteria
- CASES: HCC diagnosed without pathological examination; hepatic transplantation before the diagnosis of HCC; patients unable to answer questions; patients who do not speak French or live abroad.
- CONTROLS: History of liver cancer; other cancers under treatment except cutaneous cancers; Colonoscopy indicated in case of familial form of colon cancer; patient with cirrhosis; patients unable to answer questions; patients who do not speak French or live abroad; Relationship or same home with the case
Treatment and study plan
Primary outcomes
-
exposure to Viral hepatitis B
Time frame: Baseline
binary yes / undiagnosed by positive serology for anti-HBc antibodies isolated or associated with positive serology for anti-HBs antibodies
Secondary outcomes
-
exposure to viral hepatitis C
Time frame: baseline
binary yes / undiagnosed by positive serology for positive anti-HCV antibodies
Other outcomes
-
exposure to Alcohol
Time frame: baseline
binary variable, separating large consumers from others
-
exposure to Exogenous female hormones
Time frame: baseline
oral contraceptive coded as a binary variable
-
history of liver pathology
Time frame: baseline
binary variable: yes/no
-
Family history of liver cancer
Time frame: baseline
binary variable: yes/no
-
Diabetes
Time frame: baseline
categorical variable (depending on the type of diabetes: 1 or 2).
-
Dyslipidemias
Time frame: baseline
qualitative variables: hypercholesterolemia / hyper triglyceridemia
-
Medical treatments for dyslipidemia
Time frame: baseline
depending on the type of medication: statins, fibrates, other
-
Metabolic syndrome
Time frame: baseline
binary variable: present / absent
-
Age of first menstruation
Time frame: baseline
quantitative variable in years
-
Parity
Time frame: baseline
number of children
-
breastfeeding
Time frame: baseline
binary variable : yes / no
-
Menstrual status
Time frame: baseline
menopausal status will be treated as a binary variable
-
Duration of exposure to different variables
Time frame: baseline
quantitative variable in months
-
fruits
Time frame: baseline
frequency of intake assessed by a frequency food questionnaire
-
vegetables
Time frame: baseline
frequency of intake assessed by a frequency food questionnaire
-
meat
Time frame: baseline
frequency of intake assessed by a frequency food questionnaire
-
fish
Time frame: baseline
frequency of intake assessed by a frequency food questionnaire
-
dairy products
Time frame: baseline
frequency of intake assessed by a frequency food questionnaire
-
fats
Time frame: baseline
frequency of intake assessed by a frequency food questionnaire
Sponsors and collaborators
Lead sponsor
University Hospital, Bordeaux
Other
Collaborators
- National Cancer Institute, France
Registry information
Official study title
Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver (NoFlic Study)
Acronym: NoFlic
Important dates
- Study start
- 2010
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Feb 25, 2019
- Registry last updated
- Feb 25, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma
NCT04892810
Adenocarcinoma, Carcinoma
Grenoble, France
View Trial DetailsSHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
NCT04930315
Adenocarcinoma, Carcinoma
Hangzhou, Zhejiang, China
View Trial DetailsPressure-enabled Delivery in Radioembolization (TriNav Study)
NCT05128032
Adenocarcinoma, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsStudy of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877
Adenocarcinoma, Advanced Solid Tumor
Duarte, California, United States
View Trial Details